Pharmacy & Therapeutics - April 2008 - (Page 229) Efficacy as monotherapy and in combination In 3-month studies BYSTOLIC monotherapy achieves significant BP reductions1,2 Reductions From Baseline in Mean Sitting DBP and SBP at Trough at 3 Months 2 Placebo (n=156) SBP DBP BYSTOLIC 5 mg (n=409) SBP DBP BYSTOLIC 10 mg (n=410) SBP DBP BYSTOLIC 20 mg (n=410) SBP DBP BYSTOLIC 30/40 mg (n=166) SBP DBP 0 -2 Change From Baseline (mm Hg) -4 -6 -8 -10 -12 -14 -5.1 -4.5 -9.8 -10.8 P 55 beats per minute). Efficacy demonstrated across a broad range of patients1,2 n Studies included the following hypertensive patient populations: 42% obese (BMI ≥30 kg/m2 ), 6% poor metabolizers, 20% aged 65 years or older, 45% female, 14% Black, and 7% diabetic 2 BYSTOLIC achieves significant heart rate reductions2 n Demonstrated consistent and effective beta blockade1,2 In a 3-month combination therapy study § Additional BP reductions for patients needing add-on therapy2 n Significant DBP and SBP reductions when BYSTOLIC was added to ACEIs, ARBs, and/or diuretics2 § Results from a 3-month, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of BYSTOLIC as add-on therapy to 1 or 2 other antihypertensives (ACEIs, ARBs, and/or diuretics).
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.